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Abstract
The aim of this work was to conduct a comprehensive study about the transport properties of NSAIDs across the blood-
brain barrier (BBB) in vitro. Transport studies with celecoxib, diclofenac, ibuprofen, meloxicam, piroxicam and tenoxicam
were accomplished across Transwell models based on cell line PBMEC/C1-2, ECV304 or primary rat brain endothelial cells.
Single as well as group substance studies were carried out. In group studies substance group compositions, transport
medium and serum content were varied, transport inhibitors verapamil and probenecid were added. Resulted permeability
coefficients were compared and normalized to internal standards diazepam and carboxyfluorescein. Transport rankings of
NSAIDs across each model were obtained. Single substance studies showed similar rankings as corresponding group studies
across PBMEC/C1-2 or ECV304 cell layers. Serum content, glioma conditioned medium and inhibitors probenecid and
verapamil influenced resulted permeability significantly. Basic differences of transport properties of the investigated NSAIDs
were similar comparing all three in vitro BBB models. Different substance combinations in the group studies and addition of
probenecid and verapamil suggested that transporter proteins are involved in the transport of every tested NSAID. Results
especially underlined the importance of same experimental conditions (transport medium, serum content, species origin,
cell line) for proper data comparison.
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Introduction
The blood-brain barrier (BBB) maintains the homeostasis
between blood circulation and the central nervous system (CNS).
It consists of brain microvascular endothelial cells with distinct
different features in comparison to the peripheral endothelium.
Major brain endothelium specific properties are the lack of
fenestrae, reduced endocytosis and restricted paracellular trans-
port [1]. The barrier functionality comprises a physical, a
transporter and a metabolic component. Physical tightness of the
barrier is determined by tight junction proteins such as occludin,
claudin-3 or claudin-5 which seal the paracellular gaps and
consequently restrict the permeation of hydrophilic compounds.
Transcellular migration could be regulated by influx as well as
efflux transporter proteins. Lipophilic substances could permeate
by passive diffusion across the cell membranes or by being shuttled
via transporter proteins. Hydrophilic molecules such as glucose
need transporters such as glut1 to overcome the BBB and reach
the CNS. In addition to defend against pathogens such as viruses
or bacteria the BBB can also recognize substances and actively
efflux them back into the bloodstream. ATP-binding cassette
(ABC)-transporters such as ABCB1 (P-gp), ABCG2 (Bcrp) or
ABCCs (multidrug resistance related proteins = MRPs) play a
major role in these protection mechanisms. As third component a
huge array of enzymes can metabolize substances and prevent
their CNS entrance by molecular conversion and/or conjugation.
Barrier functionality is regulated by the microenvironment of the
capillary endothelium. The terms neuro/gliavascular unit describe
that astrocytes, pericytes and neurons can interact and modify
endothelial functional properties. In addition, shear stress by the
bloodstream applied onto endothelial cells was shown to tighten
the barrier in vitro [2–4].
Alterations of BBB functionality during several diseases such as
Alzheimer’s disease, Parkinson disease, multiple sclerosis, stroke,
traumatic brain injury and many more have been observed [5–9].
Inflammation is an important component in disease progression of
some of these diseases which could be treated by administration of
non-steroidal anti-inflammatory drugs (NSAIDs) [10]. For exam-
ple, application of ibuprofen was shown to reduce the risk to suffer
from Alzheimer’s disease [11]. NSAIDs block activity of cycloox-
ygenases (COX) with different COX1/COX2 inhibition profiles
and subsequently reduce the production of prostaglandins,
prostacycline and thromboxane A2. In general, NSAIDs reduce
fever and pain, stop inflammatory processes and could be used for
antiaggregation. In addition to side effects in the periphery such as
ulcerates, erosion in digestive tract, nausea, gastritis, bleeding,
diarrhoea or constipation, several central side effects like dizziness,
headaches and drowsiness, depressions, hearing and visual
impairment, tinnitus, etc. are known [12–14]. CNS side effects
implies BBB permeability of NSAIDs as prerequisite to reach their
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place of action. In humans as well as in several animal models it
was proved that NSAIDs can cross the BBB [15–20]. Nonetheless,
no comprehensive, systematic study about the permeability of
NSAIDs and their classification with regard to their permeability
ranking exist. Consequently, the aim of this study was to
investigate the transport of several NSAIDs across the BBB in
vitro. Transport of NSAIDs with different COX1/COX2
inhibition profiles (preferentially COX1-inhibition: ibuprofen,
piroxicam, tenoxicam; preferentially COX2-inhibition: meloxi-
cam, diclofenac; COX2-inhibition: celecoxib) was studied in three
different BBB in vitro models which differ in species origin and
barrier properties. Beginning with single substance studies, group
studies including several NSAIDs and internal standards within
one study should further elucidate the influence of different
experimental conditions (serum content, astrocyte factors, group
composition, addition of efflux transporter inhibitors verapamil
and probenecid) and provided a general view about the transport
rankings of the investigated NSAIDs.
Material and Methods
Material
Celecoxib, diclofenac, lornoxicam and diazepam were a kind
gift of Dr. Maierhofer (AGES, PharmMed, Austria), whereas
ibuprofen (I1892, SigmaAldrich, Austria), meloxicam (M3935,
SigmaAldrich, Austria), piroxicam (P5654, SigmaAldrich, Austria),
tenoxicam (T0909, SigmaAldrich, Austria), carboxyfluorescein
(21877, Fluka, Switzerland), probenecid (P8761, SigmaAldrich,
Austria) and verapamil (94837, Fluka, Switzerland) were pur-
chased from commercial sources. Iscove’s modified Dulbecco’s
medium (IMDM), Ham reg. nutrient mixture F12 (Ham’sF-12),
newborn calf serum (NCS), l-glutamine and penicillin/streptomy-
cin were obtained from Invitrogen Life technologies (GibcoTM,
Carlsbad, CA). Heparin and collagen solution (predominantly
collagen I, 150703) were purchased from MP Biomedicals (Irvine,
CA). Amphotericin B, transferrin, 8-aminopyrene-1,3,6-trisulfo-
nate (APTS) and gelatine were from SigmaAldrich (Austria),
whereas dextran (av. MW 6000) was from Fluka (Switzerland).
Fibronectin was obtained from BD Biosciences (Bedford, MA) as
well as Transwell inserts (FalconTM) and six-well plates
(FalconTM). Basal endothelial and astrocyte media and compo-
nents for primary rat endothelial cells and astrocytes were
provided from Biopredic Int. (France). Inorganic salts and all
other reagents were of analytical grade.
Cell culture
Porcine cell line PBMEC/C1-2 was a kind gift from Teifel and
Friedl, which was established and characterized by them [21].
Human ECV304 cells were purchased from the European
Collection of Cell Cultures (ECACC, Wiltshire, UK), rat glioma
cell line C6 was obtained from the German Cancer Research
Center Heidelberg (DKFZ, Heidelberg, Germany). Cell culture
conditions were previously reported [22–27]. In brief, C6 cells
were cultured in gelatin-coated 175 cm2 tissue flasks (Greiner
BioOne GmbH, Germany) with so-called C6 medium, which
consisted of a 1:1 mixture of IMDM and Ham’s F-12, 7.5% (v/v)
NCS, 7 mM L-glutamine, 5 mg/mL transferrin, 0.5 U/mL
heparin, 100 U/mL penicillin, 100 mg/mL streptomycin, and
0.25 mg/mL amphotericin B. Supernatants of C6 cultures were
collected every other day and termed glioma-conditioned medium
(GCM). PBMEC/C1-2 (passages 73–88) as well as ECV304
(passages 151–174) cells were grown in 25 cm2 gelatin-coated
tissue culture flasks with so-called PBMEC medium (50% C6
medium, 50% GCM). PBMEC medium was sterile filtered before
usage. Primary RBMECs (END105) isolated from 5 weeks old
male wistar rats and rat glial cells (AST105) derived from newborn
pups were obtained from Biopredic Int. (France) and were
cultured according to the manufacturer‘s instructions. Rat
astrocytes were grown in gelatin-coated 25 cm2 tissue flasks in
the medium provided by Biopredic Int. at passages 1–8. RBMECs
were defrozen and seeded directly onto 12-well Transwell inserts.
All cells were cultured in a humidified 5% CO2/96% humidity at
37uC and subcultivated by trypsination every 3 to 4 days.
Transport studies
6-well TranswellH inserts (1 mm pore size, PVDF) were coated
with collagen and fibronectin for PBMEC/C1-2 and with collagen
only for ECV304 cells. For permeation experiments cells were
seeded at a density of 8*104 cells/cm2 and grown to confluency on
membrane filter inserts. Culture medium was changed every day
(PBMEC/C1-2) and every other day (ECV304) up to the transport
studies. For enhanced attachment of PBMEC/C1-2 cells PBMEC
medium was supplemented with 1 mg/mL fibronectin. Cell
monolayers of PBMEC/C1-2 were used for transport studies on
day 3 and layers of ECV304 cells on day 14 after seeding. In case
of RBMEC, cells were seeded at a density of 8*104 cells/cm2 onto
12-well TranswellH inserts (1 mm pore size, PVDF), which were
coated with attachment cell factors 1:10 diluted CF1 and 1:100
diluted CF2 (175 mL/insert AFC001003; 150 mL/insert
AFC002004) for 1 hours each at 37uC (Biopredic Int., France),
in endothelial BBB culture medium (100 mL, MIL121) supple-
mented with FCS (5 mL, SER037) and additives 1-8 (400 mL
MIL045, 100 mL MIL046, 100 mL MIL047, 100 mL MIL048,
40 mL MIL049, 500 mL MIL050004, 50 mL MIL051004, 100 mL
MIL052003). Inserts were put in 12-wells containing primary rat
glial cells, which had been seeded at a density of 5*103 cells/cm2 in
glial BBB culture medium (100 mL, MIL043) supplemented with
FCS (5 mL, SER036), human AB serum (1 mL, SER035),
penicillin/streptomycin 100X (1 mL, PEN016) and additive for
glial cell medium (100 mL, MIL044) one day before. Every other
day total endothelial medium, but only half of the glial medium
was changed until TEER was over 100 Ohm*cm2 and co-culture
was ready for conduction of the transport study. Transport studies
were carried out by transferring inserts at given time points into
new wells filled with prewarmed and fresh transport medium as
previously published in detail [23]. In case of RBMEC, the
basolateral wells were filled with conditioned medium of primary
rat glial cells to exclude possible uptake of drugs by glial cells
during transport studies. TEER measurement was performed with
a Millipore Millicell Electrical Resistance System (ERS, Millipore,
Vienna, Austria) after changing the medium and temperature
equillibration at room temperature for at least 30 min. To
calculate TEER values measured electrical resistances of inserts
without cells were subtracted from values with cells and multiplied
by the surface area of the inserts (6-well: 4.2 cm2, 12-well: 0.9 cm2)
according to Neuhaus et al. (2006) [22].
Experimental solutions were prepared ‘ad hoc’ from stock
solutions. It always contained 100 mM of the respective NSAIDs
and 1% DMSO in total. Internal standards were also added
(100 mM diazepam, 5 mM carboxyfluorecein (CF) ). All solutions
were prepared under sterile conditions. At the end of transport
studies, the supernatant of the inserts was removed and analyzed
to estimate substance recovery rates. Residual applied stock
solution and samples were collected and stored until fluorescence
or HPLC analysis at 4uC. Labelling and production of APTS-
dextran for the RBMEC study was accomplished according to
protocols published recently [22].
Transport of NSAIDs across BBB In Vitro Models
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Fluorescence measurements
Fluorescence of carboxyfluorescein was determined by using a
microplate reader (polarstar galaxy, BMG Labtech, Offenburg,
Germany) at an excitation wave length of 485 nm and an emission
filter at 520 nm. Triplicates per sample were measured and blank
medium values were substracted. Fluorescence of total APTS-
dextran was measured as described above, separation and
fluorescence measurement of single APTS-dextran fractions by
capillary electrophoresis were carried out as previously published
[22].
Reverse-Phase High-Performance Liquid
Chromatography of NSAIDs
For quantification of NSAIDs a reverse-phase high-perfor-
mance liquid chromatography (RP-HPLC) system from Shimadzu
was used (DGV-20A5/prominence Degasser, SIL – 20AC/
prominence Auto Sampler, CTO – 20AC/prominence Column
Oven, SPD – 20A/prominence UV detector, CMB – 20A/
prominence Communications Bus Module). Separation of com-
pounds was carried out using Lichrospher columns from Merck
KGaA (Germany, RP-18, 25064 mm, 5 mm pore size) with
LichroCART 4-4 precolumns or Zorbax SB-C8 norrowbore
columns (820975-906, 5062.1 mm, 5 mm pore size, Inula,
Austria) with a 2.1612.5 mm precolumn packed with the same
material (821125-915, Inula, Austria). Before analysis proteins of
samples were precipitated with ice-cold methanol or acetonitril
depending on mobile phase composition and supernatants were
analyzed. Data aquisition and analysis were performed by LC-
Solution software (Shimadzu Handelsgesellschaft, Austria). Sub-
stances were analysed in triplicates with a injection volume of 20–
50 mL.Varying mixtures of methanol, acetonitrile, and 10 mM
potassium buffer (pH = 2.5 for all analysis except pH = 3.5 for
single studies with celecoxib) were used as mobile phase. Analyses
were conducted at 25uC, run time was between 8 and 18 minutes
with a flow rate of 1 or 1.3 mL/min. Substances were UV-
detected at 220 nm (diazepam, diclofenac, ibuprofen and
celecoxib in group studies), 254 nm (celecoxib in single studies)
or 370 nm (meloxicam, tenoxicam, piroxicam).
Calculation of permeability coefficients
Permeability coefficients were calculated following the clearance
principle as described recently [23]. Results of blank value
experiments were included into permeability coefficient calcula-
tion by using reciprocal correlation shown in equation (1):
1/PEcell = 1/PEall – 1/PEblank (1)
PEblank refers to the permeability coefficient without cell layer,
PEall represents the permeability coefficient through membrane
insert and the cell layer and PEcell is the permeability coefficient
only through the cell layer.
Serum binding measurements
Substance solutions with the same composition for group
transport studies in serum-free and C6 medium (100 mM
diazepam, 100 mM of each NSAID, 5 mM carboxyfluorescein,
1% DMSO end concentration) were prepared in pure PBS or C6
growth medium supplemented with 0%, 7.5%, 50% or 100%
newborn calf serum. After incubation at 37uC for 40 minutes,
2 mL of the solutions were centrifuged across prewashed (2 mL
PBS, 10 minutes, 2500 g) Centrisart ultra-filters (molecular cut-off
10 kDa, Sartorius) at 2500 g for 5 (PBS and 0% serum), 10 (7.5%
serum) or 15 (50% and 100% serum) minutes to obtain at least one
third to one half of the totally applied volume. NSAID
concentrations of stock solutions, retentates and filtrates were
analyzed by HPLC similar as described above using an Oligo-RP
clarity HPLC-column (5 mm pore size, 25064.6 mm, Phenom-
enex) at a flow rate of 1 mL/min with a 70:30 eluent mixture of
CH3CN:potassium phosphate buffer (10 mM, pH = 2.5). Carbox-
yfluorescein was measured by the microplate reader method as
described above. Unbound substance concentrations in the
filtrates were related to stock solutions to determine the serum
binding (100%-unbound fraction [%]). Blank experiments (PBS,
0% serum experiments) were included in the calculation of serum
binding values to consider systematic procedure errors and
binding of the substances to the ultrafiltration membrane.
Experiments under each condition were repeated for three times.
RT-qPCR
RT-qPCR of RBMEC lysates was accomplished according to
the protocol published previously [24]. Following primer pairs
obtained from Metabion were used: ICAM-1 forward: TTCAA-
GAATGTCTCCGAGGTCAGG, ICAM-1 reverse:
TGTTTGTGCTCTCCAGGGTCAG, VCAM-1 forward: ACA-
CAGCAGTCAAATGGAGTC, VCAM-1 reverse: AGCAGGT-
CAGGTTCACAGG, PECAM-1 forward:
GTGCTTCGGTGCTCTGTG, PECAM-1 reverse:
ATGCTGGCTCTGTTGAACG, CD44 forward: AACTA-
CAGCCTTGATGACTACC, CD44 reverse: GAT-
GACTCTTGGACTCTGATGG, Claudin-3 forward:
CCTTGCTGTGTTGCTCCTG, Claudin-3 reverse:
CGGTTGGTAGTGGTGATGG, Claudin-5 forward: GAGCA-
GAGGCACCAGAATC, Claudin-5 reverse: CAGACACAG-
CACCAGACC, Claudin-12 forward: CTGCGACTCATCA-
CATTCAAC, Claudin-12 reverse:
GTCACTGCTTCCGTCATACC, Occludin forward: TTGTA-
TAAGTCACCGCCTCTG, Occludin reverse:
TCTGTCCTCTTCGCCTTCC, ZO-1 forward: GCCAAGC-
CAGTCCATTCTC, ZO-1 reverse: AGCAT-
CAGTTTCGGGTTTCC, ACTB forward: ATCGGCAAT-
GAGCGGTTC, ACTB reverse:
ACTGTGTTGGCATAGAGGTC, GAPDH forward:
TTCAACGGCACAGTCAAGG, GAPDH reverse: CTCAG-
CACCAGCATCACC.
Immunofluorescence microscopy
RBMEC were grown on collagen coated Labtek chambered
slides (Nunc). Cells were fixed with 4% para-formaldehyde (PAF)
on ice for 10 min, and permeabilised for 5 min with 0.1% Triton
X-100 in PBS. The cells were then blocked in 10% normal goat
serum diluted in PBS for 1 h. The primary antibodies were applied
for 1 h at RT (PECAM-1: mouse, 1:50, Serotec; ZO-1: rabbit,
2.5 mg/mL, Zymed; Occludin: mouse IgG1-K 10 mg/mL, Zymed;
Claudin-3: rabbit, 10 mg/mL, Zymed; Claudin-5: mouse, 10 mg/
mL, Zymed). After 3 washes with PBS, the corresponding
fluorescence-conjugated secondary antibody (rabbit-IgG: goat,
10 mg/mL, Invitrogen; mouse-IgG: goat, 10 mg/mL, Invitrogen)
was added to the cells and incubated for 1 h. After 3 final washes,
the slides were mounted with a glass coverslip with Dako
Fluorescent Mounting Medium (DakoCytomation) and viewed
with a fluorescence microscope.
Electron microscopy
Transmission and scanning electron microscopy (TEM and
SEM) was applied to characterize RBMEC cell layers. TEM and
SEM images were generated according to the methods previously
described [27].
Transport of NSAIDs across BBB In Vitro Models
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Statistical analysis
Statistical significances between the groups, which differed in
the substance compositions, were calculated by an one-way
ANOVA. For the comparison of groups with same substance
compositions under different experimental transport conditions a
two-way ANOVA was applied followed by an all pairwise multiple
comparison procedure (Holm-Sidak method) with an overall
significance level of 0.05. Data are presented as means 6 SD
(n = 3). ANOVAs and Spearman’s ranking order correlation
coefficients were calculated by means of the software SigmaStat
3.5.
Results
Three different models were used to study the transport of
several NSAIDs (celecoxib, diclofenac, ibuprofen, meloxicam,
piroxicam and tenoxicam) across the blood-brain barrier in vitro.
The models based either on porcine cell line PBMEC/C1-2, on
human cell line ECV304 or on a co-culture system consisting of
primary rat brain microvascular endothelial cells (RBMEC) and
astrocytes (AST). After single transport studies of each investigated
NSAID across PBMEC/C1-2 and ECV304 cells, comprehensive
group transport studies under different conditions were accom-
plished in order to study the influence of serum presence, glioma
conditioned medium and addition of transporter inhibitors
verapamil and probenecid. At last a group study across the
RBMEC model was conducted in order to assess the transport
ranking of the NSAIDs across of a model which is based on
primary brain endothelial cells.
Single transport studies across PBMEC/C1-2 and ECV304
layers
First, transport studies with each NSAID (celecoxib, diclofenac,
ibuprofen, meloxicam, piroxicam and tenoxicam) alone were
accomplished across PBMEC/C1-2 or ECV304 cell layers.
Diazepam was added as internal standard for the transcellular
route, whereas carboxyfluorescein was supplemented as internal
standard for the paracellular route. Figure 1 shows the time
courses of the transport studies of piroxicam with diazepam and
carboxyfluorescein across PBMEC/C1-2 (Figure 1A) and
ECV304 (Figure 1B) cell layers. To compare these two cell line
based models to the model based on RBMECs, the same transport
experiment across RBMEC was additionally presented (Figure
1C). The linear transport of carboxyfluorescein confirmed that the
cell layers of all three models remained stable during the entire
transport experiment. Furthermore, the curves exemplified that
the cells exhibited a significant barrier for the transport of
investigated substances in comparison to the inserts without cells
(blanks). However, different permeabilities for each substance
across the inserts without cells pointed out the need of blank
studies for each compound in order to be able to calculate the
permeability coefficients across the cell layers only. As expected,
slopes of the permeability time courses of piroxicam were between
the slopes of the transcellular standard diazepam and the
paracellular standard carboxyfluorescein. Total cleared volume
values across RBMEC layers were lower in comparison to
PBMEC/C1-2 and ECV304 because RBMEC studies were
conducted with 12-well inserts, whereas PBMEC/C1-2 and
ECV304 experiments were carried out with 6-well inserts.
However, comparison of the frames of the cleared volume cell
curves between diazepam and carboxyfluorescein revealed the
smallest differences after 240 min for PBMEC/C1-2 (1.5-fold)
followed by ECV304 (3.5-fold) and RBMEC (7-fold) reflecting the
paracellular tightness of the applied layers. Results of all single
studies across PBMEC/C1-2 and ECV304 layers were summa-
rized in Table 1. Permeability coefficients (PEcell) of diazepam
across PBMEC/C1-2 layers were in average between 32.29 and
58.93 mm/min, whereas of carboxyfluorescein between 16.67 and
19.66 mm/min. On the contrary, permeability coefficients of
diazepam across ECV304 were between 19.93 and 39.95 mm/
min, whereas of carboxyfluorescein between 3.89 and 5.67 mm/
min. These data corresponded well with previous TEER and
APTS-dextran data [23] confirming that ECV304 layers were
significantly tighter than PBMEC/C1-2 layers and provide a
broader window to distinguish between the permeabilities of single
drugs. In order to account for cell layer’s variabilities permeability
coefficients of NSAIDs were normalized with the corresponding
permeability coefficient of diazepam. The resulting ratios to
diazepam were used to rank the permeability of the single
NSAIDs. Piroxicam was then the fastest substance across
PBMEC/C1-2 layers followed by tenoxicam, ibuprofen, melox-
icam, celecoxib and diclofenac. In case of the transport studies
across ECV304 layers, piroxicam was also the fastest followed by
ibuprofen, tenoxicam, celecoxib, meloxicam and diclofenac.
Comparison of the rankings across PBMEC/C1-2 and ECV304
layers resulted in a high and significant Spearman’s ranking
correlation coefficient of 0.929 (p,0.05).
Group transport studies across PBMEC/C1-2 and ECV304
layers
Comparison to single studies. No adverse effects onto the
integrity of the barrier properties of PBMEC/1-2 as well as
ECV304 layers were observed, although the number (and
according applied concentration) of NSAIDs was increased from
1 (100 mM) to maximum 6 (600 mM) NSAIDs during the group
studies. This was indicated by stable permeability values and linear
curve progressions of the internal standard for the paracellular
route carboxyfluoresein (tables 1 and 2). For example, permeabil-
ity coefficients PEcell for carboxyfluorescein were 16.67–
19.66 mm/min in PBMEC/C1-2 single studies in comparison to
18.6761.56 in the group study with all NSAIDs, and 3.89–
5.35 mm/min in ECV304 single studies in comparison to
5.5160.49 mm/min in the group study with all NSAIDs.
Normalizing the permeability coefficients of the group study to
diazepam yielded to following ranking across PBMEC/C1-2
layers: piroxicam, diazepam, ibuprofen, tenoxicam, meloxicam,
diclofenac and celecoxib, where pairs piroxicam and diazepam,
and tenoxicam and meloxicam penetrated almost equally fast. In
case of ECV304 layers, diazepam was the fastest followed by
piroxicam, ibuprofen, meloxicam, tenoxicam, diclofenac and
celecoxib. Comparison of the rankings of the single and the group
studies revealed a high Spearman’s rank order correlation
coefficient of 0.893 (p,0.05) for PBMEC/C1-2 layers and of
0.821 (p,0.05) for ECV304 layers indicating that the group
studies results showed similar permeability rankings. Minor
deviations in the rankings may occur due to drug-drug interac-
tions. Interestingly, comparison of the rankings of the group
studies across PBMEC/C1-2 and ECV304 layers also revealed a
high Spearman’s rank order correlation coefficient of 0.929 (p,
0.05). These data indicated that high correlations in the rankings
existed between the single and the corresponding group study, but
also between the two different cell lines. Based on these results, it
was decided to accomplish further group studies in order to
investigate the influence of serum, glioma derived factors, the
presence of carboxyfluorescein and meloxicam or of active
transporter inhibitors probenecid and verapamil on the perme-
ability properties of the studied NSAIDs.
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Influence of serum. In order to test the influence of the
presence of serum, group studies were conducted with NSAIDs
piroxicam, ibuprofen, meloxicam, tenoxicam and diclofenac in
serum containing and in serum-free transport medium across
PBMEC/C1-2 and ECV304 layers. Celecoxib was excluded in
this set-up due to analytical reasons. Because of the exclusion of
celecoxib, a group study in serum-containing medium without
celecoxib was accomplished as a control study for the correspond-
ing serum-free group study. Comparison of group studies
accomplished in serum-containing medium with and without
celecoxib revealed significant differences and underlined possible
drug-drug interactions of celecoxib with the transport of the other
applied compounds (table 2). In case of PBMEC/C1-2 layers,
analyzing the normalized data permeability for meloxicam
decreased from 0.5760.04-fold to 0.3860.03-fold, whereas
permeability for tenoxicam (0.5860.01 to 0.6760.00) and
carboxyfluorescein (0.4660.04 to 0.5960.04) increased signifi-
cantly (fig.2). On the contrary, exclusion of celecoxib during the
study across ECV304 layers increased only the permeability of
ibuprofen (0.4860.05 to 0.6060.03) significantly. These different
effects by celecoxib exclusion were reflected in a non-significant
Spearman’s rank order correlation coefficient of 0.5 (p = 0.217)
comparing the changed ranking of the group studies across
PBMEC/C1-2 and ECV304 without celecoxib.
Absence of serum resulted in increased absolute permeability
coefficients for almost all investigated substances in both BBB
models (table 2, except piroxicam across PBMEC/C1-2). In
comparison to the group study without celecoxib, normalized
permeability of piroxicam (1.0160.09 to 0.6860.06) decreased
significantly, whereas ibuprofen (0.5160.13 to 0.8960.06),
diclofenac (0.4260.07 to 0.8260.03) and meloxicam (0.3860.03
to 0.6560.03) migrated faster across the PBMEC/C1-2 layers
(fig.2). In case of cell line ECV304, piroxicam (0.7260.02 to
0.6260.03) and tenoxicam (0.4160.04 to 0.3160.04) permeated
significantly slower, but ibuprofen (0.6060.04 to 0.7760.03),
diclofenac (0.3860.01 to 0.6660.04) and carboxyfluorescein
(0.2060.03 to 0.2660.02) got also significantly faster when
excluding serum in the experimental set-up (fig.3). Comparing
the rankings only one significant correlation was obtained between
results of the study without celecoxib and the test in the serum-free
medium. Interestingly, the absolutely same permeability ranking
was found for the studies without serum across PBMEC/C1-2 and
ECV304 layers (Spearman’s ranking order correlation coefficient
= 1). In both cases, diazepam was the fastest substance followed by
ibuprofen, diclofenac, piroxicam, meloxicam, tenoxicam and
carboxyfluorescein.
In order to elucidate the role of serum binding of the tested
substances during these transport studies, serum binding was
measured by an ultrafiltration method. Results in the serum-
containing transport medium (7.5% serum) showed that melox-
icam (20.43%), diclofenac (52.61%) and ibuprofen (42.75%)
exhibited the highest serum binding values which was concordant
to their increased permeability ranking in the studies conducted
with serum-free medium (table 3).
Influence of glioma conditioned medium. It was
reported in several previous studies that glioma derived factors
can alter the properties of BBB in vitro models significantly [28–
30]. This was also shown for cell lines PBMEC/C1-2 and
Figure 1. Time courses of single transport studies of piroxicam
across PBMEC/C1-2, ECV304 and RBMEC layers. Comparison
between the cleared volume vs. time graphs of internal standards for
the transcellular transport route (diazepam, 100 mM), the paracellular
transport route (carboxyfluorescein, 5 mM) and the NSAID piroxicam
(100 mM) showed clearly that piroxicam permeated between the two
markers across all three BBB (A: PBMEC/C1-2; B: ECV304; C: RBMEC) in
vitro models. In addition, it was proved that as tighter the model is a
wider frame between the two markers diazepam and carboxyfluor-
escein could be provided to analyze and compare permeabilities of
single drugs. (n = 3 for each time point, data are presented as means 6
SD).
doi:10.1371/journal.pone.0086806.g001
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ECV304 [23,31]. All transport studies until now were accom-
plished in basal C6 medium. Consequently, we were interested
whether the usage of glioma conditioned medium (of this basal C6
medium) may influence the permeability of the NSAIDs investi-
gated. Comparison of the transport studies without celecoxib and
the studies in glioma conditioned medium resulted in significant
differences of the permeability behaviour of the tested drugs.
Considering normalized data, piroxicam (1.0160.09 to
0.7660.13) permeated slower and ibuprofen (0.5160.13 to
0.7560.05) as well as meloxicam (0.3860.03 to 0.6260.02)
migrated faster across PBMEC/C1-2 layers (fig.2). In case of
ECV304 cells, after normalization to diazepam all NSAIDs
(piroxicam, ibuprofen, meloxicam, tenoxicam and diclofenac) but
also the paracellular marker carboxyfluorescein penetrated signif-
Table 1. Single transport studies of NSAIDs across PBMEC/C1-2 and ECV304.
substance PSblank PSall PScell PEall PEcell Ratio to Diazepam*
[mL/min] [mL/min] [mL/min] [mm/min] [mm/min]
PBMEC/C1-2
Piroxicam study Piroxicam 8.6960.72 4.6360.36 9.9161.60 11.0260.87 23.8263.81 0.5560.05
Diazepam 8.9460.72 5.9960.35 18.1563.21 14.2760.84 43.8267.64
CF 9.4260.94 4.0160.09 7.0060.28 9.5660.22 16.6760.67
Ibuprofen study Ibuprofen 6.7260.12 3.4560.15 7.1060.65 8.22 60.36 16.9561.54 0.4660.01
Diazepam 9.2560.49 5.7660.18 15.2761.27 13.7160.43 36.4763.03
CF 11.6960.30 4.4760.08 7.2460.21 10.6560.19 17.2560.49
Meloxicam study Meloxicam 8.0361.21 3.1560.10 5.1860.28 7.5060.25 12.3460.68 0.4160.13
Diazepam 7.2860.77 4.6660.56 12.9664.28 11.1061.33 32.29610.20
CF 10.0961.18 4.1760.07 7.1260.19 9.9460.16 16.9560.46
Tenoxicam study Tenoxicam 7.476 0.31 4.1360.07 9.2560.33 9.8460.16 22.0460.78 0.4960.01
Diazepam 9.1760.47 6.1760.10 18.8660.94 14.6960.24 44.9562.24
CF 10.1660.47 4.3360.18 7.5460.54 10.3160.42 17.9961.28
Diclofenac study Diclofenac 5.8360.26 2.5260.16 4.4460.48 6.0060.38 10.6061.15 0.1860.02
Diazepam 8.0060.12 6.0460.10 24.6961.74 14.3960.25 58.9364.14
CF 10.0760.41 4.3960.08 7.7960.24 10.4660.18 18.5660.58
Celecoxib study Celecoxib 6.0760.45 2.9260.19 5.6260.71 6.9560.45 13.4461.69 0.3260.03
Diazepam 8.6460.44 5.7960.36 17.5063.20 13.7860.86 42.3067.61
CF 12.0960.36 4.9160.12 8.2560.35 11.6860.30 19.6660.83
ECV304
Piroxicam study Piroxicam 8.5360.36 3.2160.07 5.1560.19 7.6560.18 12.2760.46 0.4260.01
Diazepam 10.1360.43 5.5760.02 12.3960.11 13.2660.05 29.4960.27
CF 10.2460.30 1.6060.06 1.9060.09 3.8160.15 4.5260.20
Ibuprofen study Ibuprofen 5.5460.71 2.0260.02 3.1960.05 4.8260.05 7.6060.13 0.3160.02
Diazepam 8.2160.29 4.6060.13 11.4360.68 10.9460.32 24.8661.63
CF 10.3061.45 1.5460.11 1.8160.15 3.6760.26 4.3260.36
Meloxicam study Meloxicam 5.8060.26 1.7760.13 2.5660.27 4.2360.32 6.1060.65 0.1960.02
Diazepam 7.4960.45 4.8160.14 13.4061.14 11.4460.34 32.0062.71
CF 9.7060.66 1.6160.004 1.9260.01 3.8260.01 4.5860.01
Tenoxicam study Tenoxicam 7.1260.50 2.1660.02 3.1160.04 5.1560.05 7.4060.10 0.2860.01
Diazepam 8.9260.72 4.9760.08 11.2160.41 11.8360.19 26.7160.98
CF 11.5860.67 1.5860.08 1.8360.11 3.7760.19 4.3660.26
Diclofenac study Diclofenac 4.0860.41 1.5060.08 2.3860.19 3.5860.18 5.6760.46 0.1460.03
Diazepam 6.4661.01 4.6660.15 16.6761.88 11.0960.36 39.9564.48
CF 8.1460.30 1.3660.19 1.6360.28 3.2360.46 3.8960.67
Celecoxib study Celecoxib 5.1060.06 1.3960.17 1.9160.32 3.3160.41 4.5760.76 0.2360.02
Diazepam 10.2061.48 4.5860.34 8.3261.12 10.9160.80 19.9362.67
CF 11.4560.89 1.8860.08 2.2560.11 4.4760.18 5.3560.26
*Ratio to Diazepam is calculated by average PEcell data of the investigated NSAID and the corresponding diazepam value, CF = carboxyfluorescein.
Summary of permeability data of single transport studies with NSAIDs piroxicam, ibuprofen, meloxicam, tenoxicam, diclofenac and celecoxib across PBMEC/C1-2 as well
as ECV304 cell layers. In each transport study one NSAID was applied together with the two permeability markers diazepam and carboxyfluorescein at the same time
(n = 3, data are presented as means 6 SD).
doi:10.1371/journal.pone.0086806.t001
Transport of NSAIDs across BBB In Vitro Models
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e86806
Figure 2. Rankings of the group transport studies with NSAIDs across PBMEC/C1-2 layers. Permeability coefficient of each substance was
normalized to the corresponding permeability coefficient of internal standard diazepam of the same experiment. A): Variant substance compositions
- results of the group study with all investigated substances (diazepam, piroxicam, ibuprofen, meloxicam, tenoxicam, diclofenac, celecoxib,
carboxyfluorescein =CF) were compared to the study without celecoxib (w/o CC), without celecoxib accomplished in serum-free C6 medium (serum-
free), without celecoxib accomplished in PBMEC-Fib medium (GCM = glioma conditioned medium) and without celecoxib and carboxyfluorescein
(w/o CF). B): Different transport study conditions - results of the group study with all investigated substances (diazepam, piroxicam, ibuprofen,
meloxicam, tenoxicam, diclofenac, celecoxib, carboxyfluorescein = CF) were compared to the study without meloxicam (w/o MEL), without
meloxicam and with probenecid (with Probenecid) and without meloxicam and with verapamil (with Verapamil). To calculate the statistical
significances between the groups, which differed in the substance compositions, a one-way ANOVA was used, to compare the groups with same
substance compositions under different experimental transport conditions (in A: w/o CC, serum-free medium, GCM; in B: w/o MEL, with Probenecid,
with Verapamil) a two-way ANOVA was accomplished followed by an all pairwise multiple comparison procedure (Holm-Sidak method) with an
overall significance level of 0.05. Statistical significance (p,0.05) for each substance is indicated in the figure by * (all vs. w/o CC, all vs. w/o MEL), by#
(w/o CC vs. serum-free or GCM; w/o MEL vs. with Probenecid or with Verapamil), by 1 (serum-free vs. GCM; with Probenecid vs. with Verapamil) or by
$ (w/o CC vs. w/o CF). Data are presented as means 6 SD (n = 3).
doi:10.1371/journal.pone.0086806.g002
Transport of NSAIDs across BBB In Vitro Models
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e86806
T
a
b
le
2
.
G
ro
u
p
tr
an
sp
o
rt
st
u
d
ie
s
o
f
N
SA
ID
s
ac
ro
ss
P
B
M
EC
/C
1
-2
an
d
EC
V
3
0
4
.
P
E
c
e
ll
P
E
c
e
ll
P
E
c
e
ll
P
E
c
e
ll
P
E
c
e
ll
P
E
c
e
ll
P
E
c
e
ll
P
E
c
e
ll
[m
m
/m
in
]
[m
m
/m
in
]
[m
m
/m
in
]
[m
m
/m
in
]
[m
m
/m
in
]
[m
m
/m
in
]
[m
m
/m
in
]
[m
m
/m
in
]
se
ru
m
-f
re
e
m
e
d
iu
m
g
li
o
m
a
co
n
d
it
io
n
e
d
w
it
h
P
ro
b
e
n
e
ci
d
w
it
h
V
e
ra
p
a
m
il
w
it
h
o
u
t
C
e
le
co
x
ib
m
e
d
iu
m
w
it
h
o
u
t
C
F
w
it
h
o
u
t
M
e
lo
x
ic
a
m
w
it
h
o
u
t
M
e
lo
x
ic
a
m
w
it
h
o
u
t
M
e
lo
x
ic
a
m
su
b
st
a
n
ce
:
D
ia
ze
p
am
4
0
.0
4
6
2
.9
9
2
4
.9
1
6
2
.5
7
3
6
.6
5
6
2
.7
1
3
9
.1
8
6
2
.3
2
3
3
.9
6
6
3
.5
3
5
2
.9
6
6
5
.8
3
3
9
.1
2
6
4
.2
6
5
8
.0
3
6
5
.1
0
P
ir
o
xi
ca
m
4
1
.9
8
6
3
.8
9
2
5
.2
3
6
5
.1
0
2
4
.9
6
6
2
.0
8
2
9
.8
6
6
5
.8
4
3
0
.2
7
6
2
.6
1
3
8
.5
0
6
3
.9
6
3
0
.2
6
6
5
.8
5
4
0
.0
7
6
8
.3
9
Ib
u
p
ro
fe
n
2
5
.8
5
6
2
.6
6
1
2
.4
6
6
1
.9
5
3
2
.7
4
6
1
.5
9
2
9
.3
3
6
2
.4
5
2
4
.7
0
6
2
.6
8
2
7
.4
3
6
3
.0
6
3
2
.5
1
6
5
.5
1
4
2
.1
4
6
2
.1
1
M
e
lo
xi
ca
m
2
2
.8
7
6
2
.6
4
9
.3
9
6
0
.3
3
2
3
.7
1
6
1
.2
0
2
4
.3
2
6
1
.1
8
1
9
.9
7
6
2
.7
2
n
.a
.*
n
.a
.*
n
.a
.*
T
e
n
o
xi
ca
m
2
3
.1
0
6
1
.1
8
1
6
.6
9
6
1
.7
4
2
1
.6
7
6
0
.9
2
2
5
.8
7
6
9
.4
1
2
0
.7
4
6
1
.5
2
2
6
.8
1
6
1
.8
8
2
5
.3
2
6
1
.3
6
2
9
.1
8
6
0
.6
5
D
ic
lo
fe
n
ac
1
9
.5
0
6
1
.5
9
1
0
.2
5
6
0
.8
0
3
0
.2
0
6
2
.4
5
1
9
.8
2
6
1
.4
5
1
7
.2
2
6
1
.6
3
2
0
.4
6
6
1
.9
1
2
5
.8
0
6
2
.7
7
3
2
.3
3
6
1
.6
5
C
e
le
co
xi
b
1
3
.2
6
6
1
.0
7
n
.a
.*
n
.a
.*
n
.a
.*
n
.a
.*
1
5
.4
7
6
1
.0
2
1
6
.6
5
6
2
.2
0
2
1
.0
6
6
0
.9
1
C
F*
1
8
.6
7
6
1
.5
6
1
6
.0
2
6
1
.8
0
1
7
.6
7
6
0
.7
0
1
8
.0
1
6
1
.3
8
n
.a
.*
2
0
.6
0
6
1
.5
2
1
7
.4
1
6
0
.4
1
2
4
.6
0
6
1
.0
0
T
EE
R
[O
h
m
*c
m
2
]
5
7
.4
0
6
2
.4
2
6
0
.2
0
6
4
.2
0
5
6
.0
0
6
2
.4
2
5
7
.4
0
6
2
.4
2
5
4
.6
0
6
4
.2
0
5
6
.0
0
6
2
.4
2
6
7
.2
0
6
2
.4
2
5
8
.8
0
6
4
.8
5
su
b
st
a
n
ce
:
D
ia
ze
p
am
2
2
.7
4
6
3
.1
2
2
3
.9
3
6
2
.1
6
3
6
.7
2
6
4
.7
1
3
8
.4
4
6
3
.2
7
2
6
.4
6
6
2
.3
3
4
0
.6
9
6
5
.1
3
3
1
.4
6
6
0
.1
9
2
5
.1
5
6
2
.4
7
P
ir
o
xi
ca
m
1
2
.8
1
6
2
.6
9
1
7
.1
5
6
1
.0
0
2
2
.7
0
6
2
.0
3
1
8
.5
0
6
0
.9
3
1
8
.2
0
6
1
.5
1
2
7
.5
2
6
1
.7
4
1
7
.6
8
6
1
.3
9
1
5
.9
3
6
0
.9
3
Ib
u
p
ro
fe
n
1
0
.8
1
6
1
.0
7
1
4
.2
4
6
0
.5
7
2
8
.0
4
6
2
.4
4
8
.5
9
6
0
.4
5
1
2
.0
5
6
1
.4
2
1
6
.8
5
6
1
.2
0
1
1
.9
5
6
2
.8
3
9
.8
0
6
2
.3
7
M
e
lo
xi
ca
m
1
0
.0
5
6
0
.6
3
1
0
.7
3
6
0
.3
9
1
7
.9
6
6
0
.7
7
8
.2
2
6
1
.0
2
1
2
.1
5
6
0
.6
3
n
.a
.*
n
.a
.*
n
.a
.*
T
e
n
o
xi
ca
m
9
.9
7
6
0
.4
6
9
.8
6
6
0
.0
9
1
1
.5
5
6
2
.9
4
8
.2
3
6
0
.9
9
1
2
.9
7
6
2
.2
6
1
3
.9
6
6
0
.8
0
3
.7
9
6
0
.8
4
1
1
.9
1
6
0
.1
5
D
ic
lo
fe
n
ac
7
.7
0
6
0
.5
8
9
.0
2
6
0
.5
0
2
4
.2
9
6
1
.7
7
5
.9
3
6
0
.9
1
9
.6
5
6
0
.9
7
1
2
.6
2
6
0
.8
9
1
0
.5
3
6
0
.9
2
7
.2
4
6
0
.1
7
C
e
le
co
xi
b
6
.5
8
6
0
.5
7
n
.a
.*
n
.a
.*
n
.a
.*
n
.a
.*
1
3
.9
6
6
0
.4
1
9
.3
1
6
0
.6
0
6
.2
0
6
0
.1
9
C
F*
5
.5
1
6
0
.4
9
4
.8
4
6
0
.2
5
9
.3
8
6
0
.4
2
5
.6
4
6
0
.6
3
n
.a
.*
5
.5
9
6
0
.1
8
5
.1
2
6
0
.1
4
4
.9
2
6
0
.1
5
T
EE
R
[O
h
m
*c
m
2
]
1
2
1
.8
6
2
.4
2
1
3
4
.4
6
2
.4
2
1
2
3
.3
6
2
.4
2
1
2
4
.6
6
2
.4
2
1
2
7
.4
6
4
.8
5
1
2
8
.8
6
6
.4
2
1
3
3
.0
6
2
.4
2
1
2
7
.4
6
6
.4
2
*C
F
=
ca
rb
o
xy
fl
u
o
re
sc
e
in
,
n
.a
.
=
n
o
t
ad
d
e
d
d
u
e
to
e
xp
e
ri
m
e
n
ta
l
o
r
an
al
yt
ic
al
re
as
o
n
s.
Su
m
m
ar
y
o
f
p
e
rm
e
ab
ili
ty
d
at
a
o
f
g
ro
u
p
tr
an
sp
o
rt
st
u
d
ie
s
w
it
h
N
SA
ID
s
p
ir
o
xi
ca
m
,
ib
u
p
ro
fe
n
,
m
e
lo
xi
ca
m
,
te
n
o
xi
ca
m
,
d
ic
lo
fe
n
ac
an
d
ce
le
co
xi
b
ac
ro
ss
P
B
M
EC
/C
1
-2
as
w
e
ll
as
EC
V
3
0
4
ce
ll
la
ye
rs
.
In
e
ac
h
tr
an
sp
o
rt
st
u
d
y
th
e
tw
o
p
e
rm
e
ab
ili
ty
m
ar
ke
rs
d
ia
ze
p
am
an
d
ca
rb
o
xy
fl
u
o
re
sc
e
in
w
e
re
ap
p
lie
d
at
th
e
sa
m
e
ti
m
e
.
T
h
e
p
e
rm
e
ab
ili
ty
o
f
d
if
fe
re
n
t
g
ro
u
p
co
m
p
o
si
ti
o
n
s
(a
ll,
w
it
h
o
u
t
ce
le
co
xi
b
,
w
it
h
o
u
t
ce
le
co
xi
b
an
d
ca
rb
o
xy
fl
u
o
re
se
in
,
w
it
h
o
u
t
m
e
lo
xc
ia
m
),
in
d
if
fe
re
n
t
tr
an
sp
o
rt
m
e
d
ia
(a
ll,
se
ru
m
-f
re
e
m
e
d
iu
m
,
g
lio
m
a-
co
n
d
it
io
n
e
d
m
e
d
iu
m
)
an
d
th
e
ad
d
e
d
tr
an
sp
o
rt
e
r
in
h
ib
it
o
rs
(w
it
h
o
u
t
m
e
lo
xc
ia
m
w
it
h
p
ro
b
e
n
e
ci
d
,
w
it
h
o
u
t
m
e
lo
xi
ca
m
w
it
h
ve
ra
p
am
il)
w
as
m
e
as
u
re
d
(n
=
3
,
d
at
a
ar
e
p
re
se
n
te
d
as
m
e
an
s
6
SD
).
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
8
6
8
0
6
.t
0
0
2
Transport of NSAIDs across BBB In Vitro Models
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e86806
Figure 3. Rankings of the group transport studies with NSAIDs across ECV304 layers. Permeability coefficient of each substance was
normalized to the corresponding permeability coefficient of internal standard diazepam of the same experiment. A): Variant substance compositions
- results of the group study with all investigated substances (diazepam, piroxicam, ibuprofen, meloxicam, tenoxicam, diclofenac, celecoxib,
carboxyfluorescein =CF) were compared to the study without celecoxib (w/o CC), without celecoxib accomplished in serum-free C6 medium (serum-
free), without celecoxib accomplished in PBMEC-Fib medium (GCM = glioma conditioned medium) and without celecoxib and carboxyfluorescein
(w/o CF). B): Different transport study conditions - results of the group study with all investigated substances (diazepam, piroxicam, ibuprofen,
meloxicam, tenoxicam, diclofenac, celecoxib, carboxyfluorescein = CF) were compared to the study without meloxicam (w/o MEL), without
meloxicam and with probenecid (with Probenecid) and without meloxicam and with verapamil (with Verapamil). To calculate the statistical
significances between the groups, which differed in the substance compositions, a one-way ANOVA was used, to compare the groups with same
substance compositions under different experimental transport conditions (in A: w/o CC, serum-free medium, GCM; in B: w/o MEL, with Probenecid,
with Verapamil) a two-way ANOVA was accomplished followed by an all pairwise multiple comparison procedure (Holm-Sidak method) with an
overall significance level of 0.05. Statistical significance (p,0.05) for each substance is indicated in the figure by * (all vs. w/o CC, all vs. w/o MEL), by#
(w/o CC vs. serum-free or GCM; w/o MEL vs. with Probenecid or with Verapamil) or by 1 (serum-free vs. GCM; with Probenecid vs. with Verapamil).
Data are presented as means 6 SD (n = 3).
doi:10.1371/journal.pone.0086806.g003
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icantly slower in comparison to the study without celecoxib (fig.3).
Interestingly, transport studies of NSAIDs in glioma conditioned
medium revealed the same ranking across PBMEC/C1-2 and
ECV304 layers: diazepam was the fastest followed by piroxicam,
ibuprofen, tenoxicam, meloxicam, diclofenac and caroboxyfluor-
escein. The corresponding Spearman’s ranking order correlation
coefficient was 0.964 (p,0.05). Comparing the rankings of the
glioma conditioned medium study across PBMEC/C1-2 layers
with the corresponding control study in the basal C6 medium
resulted in no significant correlation (p.0.05), whereas in case of
ECV304 layers this comparison showed a significant Spearman’s
ranking order correlation coefficient of 0.964 (p,0.05).
Influence of carboxyfluorescein. The exclusion of carbox-
yfluoresein was done in order to investigate its possible influence
onto the permeability properties of the NSAIDs. Comparison of
these group studies with the group studies without celecoxib
revealed only one significant change. The exclusion of carboxy-
fluorescein increased the normalized permeability of ibuprofen
(0.5160.13 to 0.7360.02) in the PBMEC/C1-2 study significant-
ly. However, no significant ranking order correlation was found
for the comparisons of the studies without celecoxib and
carboxyfluorescein.
Influence of inhibitors probenecid and verapamil. In
order to test the influence of classical transporter inhibitors
probenecid, meloxicam had to be excluded from the NSAID mix
due to analytical reasons. Consequently, the differences between
the group study with all NSAIDs vs. all NSAIDs excluded
meloxicam were studied. Interestingly, the absence of meloxicam
resulted in a distinct increase of the absolute permeability
coefficients in both models (table 2). On the contrary, analyzing
the permeability coefficients normalized to diazepam, the perme-
ability of all NSAIDs except celecoxib was significantly decreased
across PBMEC/1-2 layers (fig. 2B), whereas only tenoxicam and
carboxyfluorescein decreased across ECV304 layers (fig. 3B).
Comparison of normalized data the group studies without
meloxicam vs. with probenecid revealed significant increases of
ibuprofen (0.5260.01 to 0.8360.05), tenoxicam (0.5160.02 to
0.6560.04), diclofenac (0.3960.00 to 0.6660.00) and celecoxib
(0.2960.03 to 0.4360.02) across PBMEC/C1-2, but significant
decreases of piroxicam (0.6860.04 to 0.5660.04) and tenoxicam
(0.3560.02 to 0.1260.03) across ECV304 layers. However, for all
four group studies a significant Spearman’s ranking order
correlation coefficient was found (PBMEC/C1-2 without melox-
icam vs. without melocicam, but with probenecid: 0.857, p,0.05;
ECV304 without meloxicam vs. without melocicam, but with
probenecid: 0.75, p,0.05; PBMEC/C1-2 without meloxicam vs.
ECV304 without meloxicam: 0.857, p,0.05; PBMEC/C1-2
without melocicam, but with probenecid vs. ECV304 without
melocicam, but with probenecid: 0.821, p,0.05).
The comparison of normalized data of group studies without
meloxicam vs. with verapamil showed significant increases of the
permeability of ibuprofen (0.5260.01 to 0.7360.05) and diclofe-
nac (0.3960.00 to 0.5660.02) across PBMEC/C1-2, but no
significant change across ECV304 layers. However, in this case a
significant Spearman’s ranking order correlation coefficient was
obtained for all group studies (PBMEC/C1-2 without meloxicam
vs. without melocicam, but with verapamil: 0.857, p,0.05;
ECV304 without meloxicam vs. without melocicam, but with
verapamil: 0.929, p,0.05; PBMEC/C1-2 without melocicam, but
with verapamil vs. ECV304 without melocicam, but with
verapamil: 0.786, p,0.05).
Group transport study across primary RBMEC layers
Tightness characterization of cell layers used in BBB in vitro
models is essential for the interpretation of transport study results.
The tightness of a cell layer can be described by TEER or the
permeability of a paracellular marker. The tightness properties of
the BBB in vitro model consisting of the RBMEC/AST co-culture
have not been characterized until now. Consequently, the
RBMEC cell layers and their tightness properties had to be
investigated prior drug transport studies. This was necessary in
order to be able to estimate the role of the passive, paracellular
transport route for NSAIDs across RBMEC cell layers in
comparison to PBMEC/C1-2 and ECV304 layers. The results
were summarized in figure 4. Light microscopic as well as
scanning electron microscopic (SEM) images confirmed the
spindle-like morphology of the RBMEC layers. Transmission
electron microscopy (TEM) proved that RBMECs grew as
monolayers under the established conditions (fig. 4A). At the
mRNA level, presence and the amount of major BBB tight
junction proteins occludin, ZO-1, claudin-3, claudin-5 and
claudin-12 was quantified by RT-qPCR. In addition to tight
junctional proteins, expression of endothelial markers (adhesion
molecules) PECAM-1, VCAM, ICAM-1 and CD44 was assessed
and confirmed (fig. 4B). Furthermore, the presence and correct
localisation of PECAM-1, ZO-1, occludin, claudin-3 and claudin-
5 were also confirmed by immunofluorescence microscopy at the
protein level (fig. 4C). In order to describe functional tightness,
transport studies with the paracellular marker APTS-dextran were
accomplished. Figure 4D shows on the left side a typical pattern of
the APTS-dextran ladder after a transport study, which confirmed
that the fractions with increasing glucose units permeated slower
than those with fewer glucose units indicating a molecular size
dependent paracellular permeability. On the right side a summary
of APTS-dextran permeability coefficients is given. Comparison of
the data pointed out that RBMEC layers were approximately 2.5-
fold tighter than ECV304 and 10-fold tighter than PBMEC/C1-2
layers underlining the suitability of RBMEC layers for drug
transport studies concerning the tightness of the layers.
After validation of RBMEC layers a transport group study with
NSAIDs piroxicam, ibuprofen, meloxicam, tenoxicam and diclo-
fenac was accomplished and resulted in following permeability
ranking: diazepam was the fastest followed by ibuprofen and
piroxicam (which were equally fast), diclofenac, meloxicam and
tenoxicam (table 4). This ranking was compared with the rankings
of the transport studies across PBMEC/C1-2 and ECV304 layers
in glioma conditioned medium, because the RBMEC study was
Table 3. Serum binding [%] of NSAIDs in transport media.
substance Serum concentration
7.5% 50% 100%
Diazepam 8.1760.49 19.5260.13 22.5260.06
Piroxicam 11.3061.05 61.1960.79 81.9260.06
Ibuprofen 42.7561.41 90.5260.09 92.8260.003
Meloxicam 20.4361.35 75.1460.23 84.1660.03
Tenoxicam 11.1961.81 56.3261.13 78.4760.03
Diclofenac 52.6161.36 89.3860.05 90.5760.02
CF* 17.7264.57 34.3968.87 45.8461.15
*CF = carboxyfluorescein.
Serum binding [%] of NSAIDs, diazepam and carboxyfluorescein. Serum binding
was assessed using same substance group compositions as applied for group
transport studies with C6 medium containing either 0% or 7.5% serum. Data
were presented for serum amounts of 7.5, 50 and 100% (n = 3, means 6 SD).
doi:10.1371/journal.pone.0086806.t003
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Figure 4. Characterization of the BBB model based on primary rat brain microvascular endothelial cells (RBMEC) and astrocytes.
RBMECs grow in endothelial cell typical spindle-like morphology proven by light and scanning electron microscopy (SEM). Transmission electron
microscopic (TEM) images confirmed that RBMEC grow as a monolayer. The enlarged part of the image shows two RBMECs connected to each other
directly over a pore of the Transwell insert membrane (A). mRNA expressions of tight junction proteins ZO-1, occludin, claudin-3, claudin-5 and
claudin-12, and of adhesion molecules PECAM-1, VCAM, ICAM-1 and CD44. All data were related to endogenous control GAPDH which was set to
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conducted in astrocyte conditioned medium. However, no
significant Spearman’s ranking order correlation was found
between the RBMEC and either the PBMEC/C1-2 or the
ECV304 model (correlation coefficient = 0.715, p = 0.136 in both
cases).
Discussion
The transport of NSAIDs across BBB in vitro models was
investigated in the presented work. Two major aspects of this study
should be emphasized. On the one hand no systematic study about
the permeability of several NSAIDs across the blood-brain barrier
(BBB) in vitro is available, although it is known that many NSAIDs
are able to penetrate into the CNS in vivo [15–20]. Furthermore,
NSAIDs could act beneficially in diseases such as Alzheimers
disease, epilepsy or traumatic brain injury, for which alterations of
BBB functionality were shown [5,9,11,18,32]. Consequently,
found BBB permeability ranking orders of NSAIDs in this work
may help to estimate the role of BBB permeability with regard to
their CNS effects. On the other hand rankings were assessed using
different study conditions. Especially changes of ranking orders of
studies with different experimental media underlined the impor-
tance of the used experimental medium. In order to give a
comprehensive overview three different in vitro BBB models
derived from three different species (porcine, human, rat) with
distinct different tightness properties were applied to study the
transport of several NSAIDs (celecoxib, diclofenac, ibuprofen,
meloxicam, piroxicam and tenoxicam).
Single substance studies with both cell lines revealed a transport
ranking which showed a high correlation to corresponding group
studies. As previously reported, normalization to internal standard
diazepam can be used to account for cell layer’s variabilities, which
is especially valueable for studies with cell layers of moderate
tightness [23,27,33]. Minor deviations in the rankings between
single and group studies might be explained by drug-drug
interactions. Interestingly, diclofenac outran celecoxib in the
group studies in both cell line models. Celecoxib was reported to
have the potential to block abcg2 (bcrp) functionality and thus
might increase permeability of abcg2 substrate diclofenac.
Furthermore, celecoxib could inhibit abcc4 (mrp4), to which
meloxicam can bind [34–38]. This may support that meloxicam
got ahead of celecoxib in the ECV304 group study in comparison
to corresponding single study. In summary, these facts could
explain the minor changes in the rankings between single and
group studies. Rare data of NSAID permeability across other cell
models are available. In comparison to one study with Caco-2
cells, ranking across the BBB models (piroxicam –ibuprofen –
meloxicam – diclofenac) was distinctly different to the ranking
across Caco-2 cell layers (piroxicam – diclofenac – meloxicam –
ibuprofen) [39]. Although drug-drug interactions probably occur,
group studies – also termed as cocktail studies – have proved to be
of high value for drug screenings [33,40–42]. Considering
deviations of permeability coefficients of transcellular marker
diazepam one major advantage of group studies is to obtain
permeability rankings of drugs which migrated across the same cell
layers. Therefore, it was decided to conduct further studies as
group studies to investigate the influence of varying experimental
medium, group compositions and addition of transporter inhib-
itors (verapamil, probenecid).
In general, significant congruence was obtained between group
study rankings obtained from the BBB in vitro models based on
PBMEC/C1-2 and on ECV304 cells. Lack of serum in
experimental medium revealed same rankings across both models.
Notably, with ibuprofen and diclofenac both substances containing
carboxylic acid groups migrated significantly faster in both models.
In this context, Parepally et al. (2006) reported a distinctly
decreased BBB permeability of ibuprofen with increasing amount
of plasma proteins [15]. Furthermore, they showed a saturated
transport profile for ibuprofen in studies without plasma proteins
suggesting involvement of an active transport system for ibuprofen
across the BBB. Our studies without serum confirmed these data
pointing to the important role of serum during drug transport
studies due to different drug-serum binding and consequent
lowered free drug concentrations. This was supported by our
measured serum binding values especially for ibuprofen, diclofe-
nac and meloxicam. In this case, significantly reduced amounts of
unbound drugs in the transport medium containing 7.5% serum
probably led to decreased permeability rates and minor positions
1000 (B). Immunofluorescence images of PECAM-1, ZO-1, occludin, claudin-3 and claudin-5 confirmed the protein’s presence and localization in
RBMEC layers (C). Transport studies with paracellular marker APTS-dextran ladder confirmed functionality of the barrier. RBMEC layers were able to
differentiate between the different dextran fractions in a molecular size-dependent manner. Comparison of the permeability coefficients for APTS-
dextran across PBMEC/C1-2, ECV304 and RBMEC layers is presented in the table on the right side (D).
doi:10.1371/journal.pone.0086806.g004
Table 4. Group transport study of NSAIDs across RBMEC.
substance PSblank PSall PScell PEall PEcell Ratio to Diazepam*
[mL/min] [mL/min] [mL/min] [mm/min] [mm/min]
RBMEC
group study Diazepam 1.9360.13 1.2960.02 3.7760.16 14.3560.20 41.9261.75 1.0060.00
Piroxicam 1.9460.12 1.1560.03 2.8260.17 12.7660.33 31.3961.94 0.7660.04
Ibuprofen 1.7160.15 1.0760.06 2.8660.39 11.8860.62 31.9964.28 0.7660.09
Meloxicam 1.8660.12 0.8960.02 1.7360.09 9.9760.27 19.2760.99 0.4760.02
Tenoxicam 1.7460.10 0.7060.02 1.1860.05 7.8260.21 13.1260.59 0.3260.01
Diclofenac 1.6560.13 0.9660.05 2.3960.27 10.8460.51 26.7362.97 0.6460.06
*Ratio to Diazepam is calculated by average PEcell data of the investigated NSAID and the corresponding diazepam value.
Summary of permeability data of the group study with NSAIDs piroxicam, ibuprofen, meloxicam, tenoxicam and diclofenac across the RBMEC cell layers (n = 3, data are
presented as means 6 SD).
doi:10.1371/journal.pone.0086806.t004
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in the permeability rankings within the investigated groups.
However, it should not be forgotten that serum itself could also
influence directly cell layer’s properties and consequently also drug
transport processes.
Studies with GCM highlighted the influence of astrocyte
derived factors on transport studies across BBB models. Interest-
ingly, changes in transport rankings in comparison to group
studies in C6 medium without celecoxib led to the same transport
rankings in both models. This finding seems to be very important
considering the experimental set-up of transport studies and the
role of astrocytes for barrier properties of BBB in vitro models.
Many research groups are using simplified transport buffer systems
mainly to ease drug analysis or achieve improved data compara-
bility. Our data imply distinct changes of barrier properties for
drug transport depending on the experimental transport buffer.
Even preincubation of 30–60 minutes and subsequent four hours
lasting experiments were enough to result in significant differences
of permeability coefficients. Considering our data and the
importance of astrocyte derived soluble factors for improved
barrier tightness in BBB models [28–30], it could be recom-
mended to accomplish studies in growth medium as long as the
experimental and analytical set-up allows it.
Although carboxyfluorescein had been widely used as a
paracellular marker molecule, it had also been reported being a
substrate for mrp and organic anion transporter (oat) [23,43–45].
Consequently, we have carried out group transport studies
excluding carboxyfluorescein. Notably, only permeability of
ibuprofen, which was reported to inhibit oat and mrp activity
[38,46], was increased across PBMEC/C1-2 layers. Hence, it
could be supposed that interaction of carboxyfluorescein and
ibuprofen at mrps or oats was responsible for this effect. In order
to estimate the role of active transporters during these group
transport studies general transporter inhibitors probencid and
verapamil were added. Probenecid had been published as a well-
known blocker of mrp1/2 (abcc1 and abcc2) and oats, whereas
verapamil had been used as competitive inhibitor of P-gp (abcb1)
[46–48]. Addition of probenecid increased normalized perme-
ability of ibuprofen, tenoxicam, diclofenac and celecoxib in the
PBMEC/C1-2 model, whereas decreased piroxicam and tenox-
icam migration in the ECV304 model suggesting very complex
interactions. It was reported that ibuprofen and diclofenac
inhibited mrp2, mrp4, oat1 and oat3, celecoxib blocked mrp1
and mrp4 activity and piroxicam acted as mrp2 and mrp4
inhibitor [34,37,38,46]. Thus, it could be assumed that interac-
tions at mrps and oats might lead to these changes. Addition of
verapamil increased only the normalized permeability of ibupro-
fen and diclofenac in the PBMEC/C1-2 model, although it was
shown that celecoxib can decrease P-gp activity just as diclofenac
and ibuprofen [34,49,50]. In summary, it was shown that
permeability of every investigated NSAID was altered by addition
either of transport blockers, changed transport medium or altered
substance composition.
At last a NSAID group study across a BBB model based on co-
culture of primary rat endothelial cells with astrocytes was carried
out. In comparison to the PBMEC/C1-2 and the ECV304 model,
the RBMEC/AST model exhibited significantly higher paracel-
lular tightness reflected in low APTS-dextran permeability and
high TEER values. In addition to the high tightness, RBMEC/
AST were chosen in order to include a model derived from a
rodent species, in particular from rat, since pig (PBMEC/C1-2)
and human (ECV304) are genetically very cognate [51]. Char-
acterisation of the model proved monolayer structure, major
tightness properties and endothelial marker expression confirming
suitability of this model as BBB model. In general, similar
tendencies were shown as compared to transport results obtained
with PBMEC/C1-2 and ECV304 models. For example, ibuprofen
and piroxicam were the fastest after diazepam. However,
moderate differences were found. In particular ibuprofen overran
piroxicam, and diclofenac overran meloxicam and tenoxicam,
which in the end led to no significant ranking correlation between
the primary rat RBMEC/AST model and the porcine PBMEC/
C1-2 and human ECV304 model. In this context, it should be
considered that species specific properties might be responsible for
these differences.
Conclusion
NSAIDs permeated across used BBB in vitro models well
confirming in vivo data about BBB permeability and CNS side
effects of NSAIDs. High correlations were found between
transport rankings of NSAIDs across both PBMEC/C1-2 and
ECV304 cell layers. Group transport studies revealed similar
results as single substance studies yielding in high correlation
coefficients which confirmed usefulness of the application of group
studies. Varying transport medium underlined the impact of the
experimental transport buffer on the results and led to the
recommendation to use astrocyte conditioned medium for
transport studies. Altered compositions of studied NSAID groups
and addition of transporter protein inhibitors showed that their
transport were regulated by drug-drug interactions, presumably at
the site of drug transporter proteins. In conclusion, the presented
work provides a comprehensive overview of transport rankings of
NSAIDs across three BBB in vitro models and highlighted the
influence of the experimental conditions on these transport
rankings.
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